Bavarian Nordic A/S (CPH: BAVA), a fully integrated biotechnology company focused on the development of innovative therapies against infectious diseases and cancer, announced on Friday that the stage 1 of the phase 2 study evaluating the combination therapy of its cancer immunotherapy, CV301, and Roches's checkpoint inhibitor, atezolizumab (TECENTRIQ), for the treatment of patients with locally advanced or metastatic urothelial bladder cancer did not meet the efficacy threshold to progress into stage 2 with expanded enrollment.
Also, no serious adverse events were observed in the study to date.
Reportedly, in the first stage of the trial, 27 patients were enrolled into two cohorts: the first cohort was first-line treatment of patients (n=14) with urothelial bladder cancer who were not eligible for cisplatin-containing chemotherapy; and cohort 2 was a second-line treatment of patients (n=13) who had previously been treated with cisplatin-based chemotherapies.
Despite the detection of clinical efficacy in a number of patients, neither cohort met the pre-defined criteria for clinical efficacy to expand enrollment into the second stage of the trial.
This study was sponsored by Bavarian Nordic and two other, investigator-sponsored phase 2 trials evaluating CV301 in combination with checkpoint inhibitors, are still ongoing in colorectal and pancreatic cancer.
Bavarian Nordic added that it will continue to follow and support these ongoing trials, while the company's primary focus and resources will be directed towards BN-Brachyury and the new immuno-oncology strategy involving intravenous and intratumoral administration, as well as new and more advanced constructs.
In addition, the company's novel vaccine candidate, BN-Brachyury, is currently being evaluated in a phase 2 trial in patients with advanced chordoma. This trial, which also uses a two-stage design, indicated clinical activity in the first stage, allowing for expansion of enrollment, which was recently completed. Conclusive data from this study are expected within 12 months. Another trial of BN-Brachyury administered intravenously is planned and will initiate shortly.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial